Boosting delivery of LAT1-targeted boron carriers for improved boron neutron capture therapy

Description of the granted funding

Glioblastoma multiforme (glioma) is a disease of the entire brain. Both primary and metastatic brain tumors have limited treatment options and long-term survival is rare. Even in the face of aggressive treatment, brain tumor growth and recurrence are unavoidable, due mainly to ineffective delivery of therapeutic agents across the blood-brain barrier (BBB). The BBB in the tumor core is "leaky", allowing systemic drug delivery, but glioma cells infiltrate normal brain structures centimeters away from the margin of surgical resection where the BBB is intact. In this project, the enhanced expression and transport capacity of large neutral amino acid transporter (LAT1) both at the BBB and in glioma cells is utilized to develop novel LAT1-targeted boron carriers for boron neutron capture therapy (BNCT) to be used in the treatment of gliomas.
Show more

Starting year

2024

End year

2027

Granted funding

Jarkko Rautio Orcid -palvelun logo
497 191 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Decision maker

Scientific Council for Biosciences, Health and the Environment
30.05.2023

Other information

Funding decision number

355312

Fields of science

Pharmacy

Research fields

Farmasia

Identified topics

cancer